Skip Navigation

Mark Awad, MD, PhD


Medical Oncology

Make an Appointment

Physician

  • Physician
  • Assistant Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Immunotherapy
  • Lung cancer
  • Mesothelioma
  • Targeted therapies

Diseases Treated

  • Lung Cancer, non-small cell
  • Lung Cancer, small cell
  • Mesothelioma

Contact Information

  • Appointments877-332-4294 (new)
    617-632-6190 (established)
  • Office Phone Number617-632-3468
  • Fax617-632-5786

Bio

Dr. Awad received his MD and PhD from the Johns Hopkins School of Medicine in 2008.  He completed his residency and chief residency in internal medicine at the Massachusetts General Hospital.  He received his fellowship training in medical oncology at the Dana-Farber/ Partners CancerCare program and joined the faculty in the Lowe Center for Thoracic Oncology at Dana-Farber in 2014.  His research focuses on understanding mechanisms of response and resistance to immunotherapy in lung cancer and mesothelioma, and he is involved in developing novel therapies for lung cancers with mutations in genes such as MET, RET, ALK, and ROS1.

Board Certification:

  • Internal Medicine, 2011
  • Medical Oncology, 2014

Fellowship:

  • Dana-Farber/Partners CancerCare, Hematology/Oncology

Residency:

  • Massachusetts General Hospital, Chief Resident, Internal Medicine
  • Massachusetts General Hospital, Internal Medicine

Medical School:

  • Johns Hopkins School of Medicine

Recent Awards:

  • Young Investigator Award (YIA), American Society of Clinical Oncology (ASCO) 2015
  • Young Investigator Award (YIA), International Association for the Study of Lung Cancer (IASLC) 2015
  • Lung Cancer Developmental Research Award, Dana-Farber / Harvard Cancer Center 2015
  • Koch Institute Expansion Bridge Grant Recipient 2016

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston MA, 02215
Get Directions

Research

Immunotherapies and Vaccine Development

Dr. Awad's main area of research is on cancer immunotherapy and vaccine development.  He has been working with a number of laboratories to study the genetics and immune microenvironemnt of lung tumors in order to develop better immune therapies for cancer patients.  In addition, he conducts research on cancers whose growth is driven by mutations in genes such as RET, ROS1, and ALK, and he has been working to understand how these cancers acquire resistance to targeted therapies.

Top